Quellenangaben: Innovationen bei der Thromboseprophylaxe- und Behandlung
[1] Kishimoto, T. K.; Viswanathan, K.; Ganguly, T.; Elankumaran, S.;
Smith, S.; Pelzer, K.; Lansing, J. C.; Sriranganathan, N.; Zhao, G.;
Galcheva-Gargova, Z.; Al-Hakim, A.; Bailey, G. S.; Fraser, B.; Roy, S.;
Rogers-Cotrone, T.; Buhse, L.; Whary, M. und Fo: Contaminated Heparin
Associated with Adverse Clinical Events and Activation of the Contact
System. N Engl J Med, 2008[2] Turpie, A. G.; Bauer, K. A.; Eriksson, B. I. und Lassen, M. R.: Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med, 2002, 162(16), S.1833-1840
[3] Agnelli, G.; Bergqvist, D.; Cohen, A. T.; Gallus, A. S.; Gent, M. und CN- PEGASUS, i. nvestigators.: Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg, 2005, 92(10), S.1212-1220
[4] Cohen, A. T.; Davidson, B. L.; Gallus, A. S.; Lassen, M. R.; Prins, M. H.; Tomkowski, W.; Turpie, A. G.; Egberts, J. F.; Lensing, A. W. und CN- ARTEMIS, I. nvestigators.: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ, 2006, 332(7537), S.325-329
[5] Anderson, J. L.; Adams, C. D.; Antman, E. M.; Bridges, C. R.; Califf, R. M.; Casey DE, J. r.; Chavey WE, 2. nd.; Fesmire, F. M.; Hochman, J. S.; Levin, T. N.; Lincoff, A. M.; Peterson, E. D.; Theroux, P.; Wenger, N. K.; Wright, R. S. und Smith SC, J. r.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revi. J Am Coll Cardiol, 2007, 50(7), S.e1-e157
[6] Bassand, J. P.; Hamm, C. W.; Ardissino, D.; Boersma, E.; Budaj, A.; Fernandez-Aviles, F.; Fox, K. A.; Hasdai, D.; Ohman, E. M.; Wallentin, L. und Wijns, W.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007, 28(13), S.1598-660 CN- Task Force f
[7] Buller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; van den, B. erg-Segers AE.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W. und CN- Matisse, I. nvestigators.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med, 2003, 349(18), S.1695-1702
[8] Buller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; Segers, A. E.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W. und CN- Matisse, I. nvestigators.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med, 2004, 140(11), S.867-873
[9] Fachinformation des Arzneimittel-Kompendiums der Schweiz: Arixtra. Documed, Basel, 2008
[10] Thielicke, Robert: Heparin-Skandal: Tod bewusst in Kauf genommen. URL: http://www.focus.de/gesundheit/arzt_medikamente/
heparin-skandal-tod-bewusst-in-kauf-genommen_aid_297434.html?omiid=rss, Focus Online, München, Abruf: 28.04.2008